Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
5 "Ho Cheol Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Factors Associated with Postoperative Recurrence in Stage I to IIIA Non–Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: Analysis of Korean National Population Data
Kyu Yean Kim, Ho Cheol Kim, Tae Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang Gun Suh, Chang Hoon Song, Jin Seok Ahn, Jeong Eun Lee, Jae Hyun Jeon, Chi Young Jung, Jeong Su Cho, Yoo Duk Choi, Seung Sik Hwang, Chang Min Choi, Seung Hun Jang, Jeong Uk Lim, Korean Association for Lung Cancer, Korea Central Cancer Registry
Received January 19, 2024  Accepted July 8, 2024  Published online July 10, 2024  
DOI: https://doi.org/10.4143/crt.2024.073    [Epub ahead of print]
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Recent development in perioperative treatment of resectable non–small cell lung cancer (NSCLC) have changed the landscape of early lung cancer management. The ADAURA trial has demonstrated the efficacy of adjuvant osimertinib treatment in resectable NSCLC patients; however, studies are required to show which subgroup of patients are at a high risk of relapse and require adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor treatment. This study evaluated risk factors for postoperative relapse among patients who underwent complete resection.
Materials and Methods
Data were obtained from the Korean Association for Lung Cancer Registry (KALC-R), a database created using a retrospective sampling survey by the Korean Central Cancer Registry (KCCR) and the Lung Cancer Registration Committee.
Results
A total of 3,176 patients who underwent curative resection was evaluated. The mean observation time was approximately 35.4 months. Among stage I to IIIA NSCLC patients, the EGFR-mutant subgroup included 867 patients, and 75.2%, 11.2%, and 11.8% were classified as stage I, stage II, and stage III, respectively. Within the EGFR-mutant subgroup, 44 (5.1%) and 121 (14.0%) patients showed early and late recurrence, respectively. Multivariate analysis on association with postoperative relapse among the EGFR-mutant subgroup showed that age, pathologic N and TNM stages, pleural invasion status, and surgery type were independent significant factors.
Conclusion
Among the population that underwent complete resection for early NSCLC with EGFR mutation, patients with advanced stage, pleural invasion, or limited resection are more likely to show postoperative relapse.
  • 1,207 View
  • 78 Download
Close layer
Lung and Thoracic cancer
Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung-Sik Hwang, Chang-Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry
Cancer Res Treat. 2023;55(1):103-111.   Published online June 20, 2022
DOI: https://doi.org/10.4143/crt.2022.264
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.
Materials and Methods
The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.
Results
We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).
Conclusion
In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.

Citations

Citations to this article as recorded by  
  • Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
    Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim
    Cancer Research and Treatment.2024; 56(1): 104.     CrossRef
  • The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round
    Alberto Antonicelli, Piergiorgio Muriana, Giovanni Favaro, Giuseppe Mangiameli, Ezio Lanza, Manuel Profili, Fabrizio Bianchi, Emanuela Fina, Giuseppe Ferrante, Simone Ghislandi, Daniela Pistillo, Giovanna Finocchiaro, Gianluigi Condorelli, Rosalba Lembo,
    Cancers.2024; 16(2): 417.     CrossRef
  • Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
    Hyeon Hwa Kim, Jae Cheol Lee, In-Jae Oh, Eun Young Kim, Seong Hoon Yoon, Shin Yup Lee, Min Ki Lee, Jeong Eun Lee, Chan Kwon Park, Kye Young Lee, Sung Yong Lee, Seung Joon Kim, Jun Hyeok Lim, Chang-min Choi
    Cancers.2024; 16(3): 528.     CrossRef
  • Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation
    Theofanis Vavilis, Maria Louiza Petre, Giannis Vatsellas, Alexandra Ainatzoglou, Eleni Stamoula, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas, Ioannis N. Vamvakaris, Ioannis Gkiozos, Konstantinos N. Syrigos, Athanasios K. Anagnostopoulos
    Cancers.2024; 16(6): 1236.     CrossRef
  • Survival analysis and gender differences in hypertrophic cardiomyopathy proband patients referred for genetic testing
    Rebeca Lorca, María Salgado, Rut Álvarez-Velasco, Julián R. Reguro, Vanesa Alonso, Juan Gómez, Eliecer Coto, Elías Cuesta-Llavona, Eva Lopez-Negrete, Isaac Pascual, Pablo Avanzas, Maite Tome
    International Journal of Cardiology.2024; 408: 132117.     CrossRef
  • 18F-Fluorodeoxyglucose Positron Emission Tomography-Based Risk Score Model for Prediction of Five-Year Survival Outcome after Curative Resection of Non-Small-Cell Lung Cancer
    Chae Hong Lim, Sang-Won Um, Hong Kwan Kim, Yong Soo Choi, Hong Ryul Pyo, Myung-Ju Ahn, Joon Young Choi
    Cancers.2024; 16(14): 2525.     CrossRef
  • Study Progress of Circulating miRNA for Predicting Metastasis in Non-Small Cell Lung Cancer
    靖靖 丛
    Advances in Clinical Medicine.2024; 14(07): 65.     CrossRef
  • Toll-like Receptors: Key Players in Squamous Cell Carcinoma Progression
    Jolanta Smok-Kalwat, Paulina Mertowska, Sebastian Mertowski, Stanisław Góźdź, Ewelina Grywalska
    Journal of Clinical Medicine.2024; 13(15): 4531.     CrossRef
  • Timing of Palliative Care Consultation Impacts End of Life Care Outcomes in Metastatic Non-Small Cell Lung Cancer
    Cameron J. Oswalt, Morgan M. Nakatani, Jesse Troy, Steven Wolf, Susan C. Locke, Thomas W. LeBlanc
    Journal of Pain and Symptom Management.2024; 68(4): e325.     CrossRef
  • Enhanced Lung Cancer Detection Using a Combined Ratio of Antigen–Autoantibody Immune Complexes against CYFRA 21-1 and p53
    Heyjin Kim, Jin Kyung Lee, Hye-Ryoun Kim, Young Jun Hong
    Cancers.2024; 16(15): 2661.     CrossRef
  • Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosome DNA Methylation Profile
    Chinbayar Batochir, In Ae Kim, Eun Ji Jo, Eun-Bi Kim, Hee Joung Kim, Jae Young Hur, Do Won Kim, Hee Kyung Park, Kye Young Lee
    Cancers.2024; 16(15): 2765.     CrossRef
  • The clinical significance of endoplasmic reticulum stress related genes in non-small cell lung cancer and analysis of single nucleotide polymorphism for CAV1
    Shuang Li, Junting Chen, Baosen Zhou
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • A Highly Sensitive Toluene Gas Sensor Based on Pd/PdO Decorated SnO2 Prepared by Electrospinning
    Chengyi Gong, Meng Chen, Fei Song, Peisi Yin, Xin Zhao, Xiaoyu You, Huaian Fu, Shanshan Yu, Xingyu Liu, Kai Zhang, Yongqi Yang, Zhipeng Tang, Xiangmin Du, Jiacong Xu, Qiang Jing, Bo Liu
    ACS Applied Electronic Materials.2024;[Epub]     CrossRef
  • miR-137: a potential therapeutic target for lung cancer
    Shuanshuan Liu, Yanyun Ruan, Xu Chen, Bao He, Qi Chen
    Frontiers in Cell and Developmental Biology.2024;[Epub]     CrossRef
  • Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis
    Junfang Zhang, Xuan Tang, Wenbo Zhang, Ying Xu, Heng Zhang, Yu Fan
    International Journal of Obesity.2024;[Epub]     CrossRef
  • Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer
    Tianxing Hu, Jiali Huang, Rui Chen, Hui Zhang, Mai Liu, Renbing Wang, Wenyi Zhou, Dechun Huang, Mingkang Cao, Depeng Li, Zhiyu Li, Hongxi Wu, Jinlei Bian
    European Journal of Medicinal Chemistry.2024; 280: 116952.     CrossRef
  • CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
    Suet Kee Loo, Gabriel Sica, Xian Wang, Tingting Li, Luping Chen, Autumn Gaither-Davis, Yufei Huang, Timothy F. Burns, Laura P. Stabile, Shou-Jiang Gao
    Cell & Bioscience.2024;[Epub]     CrossRef
  • Methylation modification is a poor prognostic factor in non-small cell lung Cancer and regulates the tumor microenvironment: mRNA molecular structure and function
    Kai Yang, YuPing Yang, Lin Yu, Fan Yang, YuXin Xiang, Jun Zeng, Na Huang
    International Journal of Biological Macromolecules.2024; 282: 137214.     CrossRef
  • Impact of Postoperative Prolonged Air Leakage on Long-Term Pulmonary Function after Lobectomy for Lung Cancer
    June Yeop Lee, Joonseok Lee, Varissara Javakijkarnjanakul, Beatrice Chia-Sui Shih, Woohyun Jung, Jae Hyun Jeon, Kwhanmien Kim, Sanghoon Jheon, Sukki Cho
    Journal of Chest Surgery.2024; 57(6): 511.     CrossRef
  • M1 macrophage-related prognostic model by combining bulk and single-cell transcriptomic data in NSCLC
    Liu Zhe, Liu Fang, Petinrin Olutomilayo Olayemi, Toseef Muhammad, Chen Nanjun, Zhu Zhongxu, Wong Ka-Chun
    Exploration of Medicine.2024;[Epub]     CrossRef
  • Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection
    Silvia D’Ambrosi, Stavros Giannoukakos, Mafalda Antunes-Ferreira, Carlos Pedraz-Valdunciel, Jillian W. P. Bracht, Nicolas Potie, Ana Gimenez-Capitan, Michael Hackenberg, Alberto Fernandez Hilario, Miguel A. Molina-Vila, Rafael Rosell, Thomas Würdinger, Da
    International Journal of Molecular Sciences.2023; 24(5): 4881.     CrossRef
  • Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer: a single-center analysis of 10 years
    Jee Seon Kim, Eun Ji Kim, Jong Geol Jang, Kyung Soo Hong, June Hong Ahn
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7275.     CrossRef
  • Prior treated tuberculosis and mortality risk in lung cancer
    Kuang-Ming Liao, Chung-Shu Lee, Yu-Cih Wu, Chin-Chung Shu, Chung-Han Ho
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • All-round counterattack to conquer lung cancer
    Seung Hun Jang
    Journal of the Korean Medical Association.2023; 66(3): 154.     CrossRef
  • Metabolic profiles of lung adenocarcinoma via peripheral blood and diagnostic model construction
    Kyung Soo Kim, Seok Whan Moon, Mi Hyung Moon, Kwan Yong Hyun, Seung Joon Kim, Young Koon Kim, Kwang Youl Kim, Dong Wook Jekarl, Eun-Jee Oh, Yonggoo Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • STEMI in women. Life expectancy recovery after primary percutaneous coronary intervention
    Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
    Revista Española de Cardiología (English Edition).2023; 76(12): 1003.     CrossRef
  • A Retrospective Analysis Comparing VATS Cost Discrepancies and Outcomes in Primary Lung Cancer vs. Second Primary Lung Cancer Patients
    Bogdan Cosmin Tanase, Alin Ionut Burlacu, Claudiu Eduard Nistor, Teodor Horvat, Cristian Oancea, Monica Marc, Emanuela Tudorache, Tudor Mateescu, Diana Manolescu
    Healthcare.2023; 11(12): 1745.     CrossRef
  • IAMCEST en mujeres. Recuperación de la expectativa de vida tras la intervención coronaria percutánea
    Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
    Revista Española de Cardiología.2023; 76(12): 1003.     CrossRef
  • Synthetic Tabular Data Based on Generative Adversarial Networks in Health Care: Generation and Validation Using the Divide-and-Conquer Strategy
    Ha Ye Jin Kang, Erdenebileg Batbaatar, Dong-Woo Choi, Kui Son Choi, Minsam Ko, Kwang Sun Ryu
    JMIR Medical Informatics.2023; 11: e47859.     CrossRef
  • Exosomes in lung cancer metastasis, diagnosis, and immunologically relevant advances
    Jianhua Zhao, Xiwen Li, Lele Liu, Zhen Zhu, Chunyan He
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • 8,727 View
  • 426 Download
  • 35 Web of Science
  • 30 Crossref
Close layer
Lung Cancer
Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population
Ho Cheol Kim, Wonjun Ji, Jae Cheol Lee, Hyeong Ryul Kim, Si Yeol Song, Chang-Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry
Cancer Res Treat. 2021;53(4):1033-1041.   Published online February 16, 2021
DOI: https://doi.org/10.4143/crt.2020.1350
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The optimal treatment for patients with stage III non-small cell lung cancer (NSCLC) remains controversial. This study aimed to investigate prognostic factors and clinical outcome in stage III NSCLC using real-world clinical data in the Korean population.
Materials and Methods
Among 8,110 patients with lung cancer selected from 52 hospitals in Korea during 2014-2016, only patients with stage III NSCLC were recruited and analyzed. A standardized protocol was used to collect clinical information and cox proportional hazards models were used to identify risk factors for mortality.
Results
A total of 1,383 patients (46.5% had squamous cell carcinoma and 40.9% had adenocarcinoma) with stage III NSCLC were enrolled, and their median age was 70 years. Regarding clinical stage, 548 patients (39.6%) had stage IIIA, 517 (37.4%) had stage IIIB, and 318 (23.0%) had stage IIIC. Pertaining to the initial treatment method, the surgery group (median survival period: 36 months) showed better survival outcomes than the non-surgical treatment group (median survival period: 18 months, p=0.001) in patients with stage IIIA. Moreover, among patients with stage IIIB and stage IIIC, those who received concurrent chemotherapy and radiation therapy (CCRT, median survival period: 24 months) showed better survival outcomes than those who received chemotherapy (median survival period: 11 months), or radiation therapy (median survival period: 10 months, p<0.001).
Conclusion
While surgery might be feasible as the initial treatment option in patients with stage IIIA NSCLC, CCRT showed a beneficial role in patients with stage IIIB and IIIC NSCLC.

Citations

Citations to this article as recorded by  
  • Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
    Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
    Cancer Medicine.2024;[Epub]     CrossRef
  • Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: Insights from Real-World Data
    Jeong Yun Jang, Si Yeol Song, Young Seob Shin, Ha Un Kim, Eun Kyung Choi, Sang-We Kim, Jae Cheol Lee, Dae Ho Lee, Chang-Min Choi, Shinkyo Yoon, Su Ssan Kim
    Cancer Research and Treatment.2024; 56(3): 785.     CrossRef
  • Glucose metabolic heterogeneity correlates with pathological features and improves survival stratification of resectable lung adenocarcinoma
    Yu-Hung Chen, Yen-Chang Chen, Kun-Han Lue, Sung-Chao Chu, Bee-Song Chang, Ling-Yi Wang, Ming-Hsun Li, Chih-Bin Lin
    Annals of Nuclear Medicine.2023; 37(2): 139.     CrossRef
  • The combined tumor-nodal glycolytic entropy improves survival stratification in nonsmall cell lung cancer with locoregional disease
    Yu-Hung Chen, Kun-Han Lue, Sung-Chao Chu, Bee-Song Chang, Chih-Bin Lin
    Nuclear Medicine Communications.2023; 44(1): 100.     CrossRef
  • Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis
    Yong-Jin Park, Yunjoo Im, O. Jung Kwon, Joungho Han, Myung-Ju Ahn, Jhingook Kim, Sang-Won Um, Joon Young Choi
    Scientific Reports.2023;[Epub]     CrossRef
  • A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
    Cheol-Kyu Park, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, In-Jae Oh
    Cancers.2023; 15(5): 1606.     CrossRef
  • Association between clinical outcomes and local treatment in stage IV non‐small cell lung cancer patients with single extrathoracic metastasis
    Jeong Uk Lim, Hye Seon Kang, Ah Young Shin, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
    Thoracic Cancer.2022; 13(9): 1349.     CrossRef
  • Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review
    Guohua Jia, Shuimei Zhou, Tangpeng Xu, Yabing Huang, Xiangpan Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiatio
    Juwhan Choi, Jeong Eun Lee, Chang‐Min Choi, In‐Jae Oh, Kye Young Lee, Tae Won Jang, Seung Hyeun Lee, Eun Young Kim, Dong Won Park, Sun Hyo Park, Sung Yong Lee
    Thoracic Cancer.2022; 13(23): 3431.     CrossRef
  • Prognostic Value of Combing Primary Tumor and Nodal Glycolytic–Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis
    Yu-Hung Chen, Sung-Chao Chu, Ling-Yi Wang, Tso-Fu Wang, Kun-Han Lue, Chih-Bin Lin, Bee-Song Chang, Dai-Wei Liu, Shu-Hsin Liu, Sheng-Chieh Chan
    Diagnostics.2021; 11(6): 1065.     CrossRef
  • 7,677 View
  • 215 Download
  • 10 Web of Science
  • 10 Crossref
Close layer
Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014
Chang-Min Choi, Ho Cheol Kim, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Seung Joon Kim, Yeongdae Kim, Yoo-Duk Choi, Yang-Gun Suh, Jung-Eun Kim, Boram Lee, Young-Joo Won, Young-Chul Kim
Cancer Res Treat. 2019;51(4):1400-1410.   Published online February 25, 2019
DOI: https://doi.org/10.4143/crt.2018.704
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The aim of this study was to investigate epidemiology, clinical characteristics and sex differences of patients with lung cancer using nationwide registry in Korea.
Materials and Methods
The Korean Association for Lung Cancer developed a registry in cooperation with the Korean Central Cancer Registry, and surveyed about 10% of lung cancer cases. For this first survey of cases diagnosed in 2014, cases were selected through a systematic sampling method.
Results
Total 2,621 lung cancer patients were surveyed, and the median patient age was 70 years. During the study period, adenocarcinoma was the most frequent histologic type, the proportion of female patients was 28.4%, and women had a better prognosis (median survival, not reached vs. 13 months; p<0.001) than did men for non-small cell lung cancer. The proportion of never-smokers was 36.4%, and never-smoking was more prevalent in women than in men (87.5 vs. 16.0%, p<0.001). Epidermal growth factor receptor (EGFR) mutations were found in 36.8% of stage IV adenocarcinoma patients, and higher in female compared to male patients (51.2 vs. 26.6%, p<0.001). In addition, patients with EGFR mutation showed better survival (median survival, 18 vs. 8 months; p<0.001) than patients without EGFR mutation in these patients.
Conclusion
This is the first survey to gather unbiased nationwide lung cancer statistics in Korea. More than one-third of lung cancer patients had no smoking history. Female had a high proportion of non-smoker, more adenocarcinoma with EGFR mutation and generally better prognosis than male.

Citations

Citations to this article as recorded by  
  • Prognostic value of electronic health records-based frailty measures for all-cause mortality in older patients with non-small cell lung cancer
    Minh-Thao Tu, Thi-Ngoc Tran, Hoejun Kwon, Yoon-Jung Choi, Youngjoo Lee, Hyunsoon Cho
    Journal of Geriatric Oncology.2025; 16(1): 102130.     CrossRef
  • Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel
    Fuyumi Nishihara-Kato, Hisao Imai, Takeshi Tsuda, Satoshi Wasamoto, Yoshiaki Nagai, Takayuki Kishikawa, Yosuke Miura, Akihiro Ono, Yutaka Yamada, Ken Masubuchi, Takashi Osaki, Junichi Nakagawa, Yukihiro Umeda, Hiroyuki Minemura, Yuki Kozu, Hirokazu Tanigu
    Oncology.2024; 102(1): 30.     CrossRef
  • Diagnostic challenge and survival analysis of pulmonary oligometastases and primary lung cancer in breast cancer patients
    Siyao Mai, Haiqing Liu, Hong Zeng, Ziliang Cheng, Jingwen Huang, Guangzi Shi, Yong Li, Zhuo Wu
    Thoracic Cancer.2024; 15(12): 1017.     CrossRef
  • Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
    Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
    Cancer Medicine.2024;[Epub]     CrossRef
  • Sex differences in prognosis factors in patients with lung cancer: A nationwide retrospective cohort study in Korea
    Youn Huh, Yeo Ju Sohn, Hae-Rim Kim, Hyejin Chun, Hwa Jung Kim, Ki Young Son, Dong Keon Yon
    PLOS ONE.2024; 19(5): e0300389.     CrossRef
  • Glycemic status, insulin resistance, and mortality from lung cancer among individuals with and without diabetes
    In Young Cho, Yoosoo Chang, Eunju Sung, Boyoung Park, Jae-Heon Kang, Hocheol Shin, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
    Cancer & Metabolism.2024;[Epub]     CrossRef
  • Mitochondrial Dynamics in Non-Small Cell Lung Cancer
    Agata Dutkowska, Daria Domańska-Senderowska, Karolina H. Czarnecka-Chrebelska, Ewa Pikus, Aleksandra Zielińska, Laura Biskup, Agata Kołodziejska, Paulina Madura, Maria Możdżan, Urszula Załuska, Edward Zheng, Eliza Adamczyk, Konrad Kędzia, Szymon Wcisło, M
    Cancers.2024; 16(16): 2823.     CrossRef
  • Gender‐specific outcomes of low‐dose computed tomography screening for lung cancer detection: A retrospective study in Chinese never‐smoker population
    Huihong Wang, Jicheng Xie, Yahong Chen, Jiang Jin, Meixian Zhang, TaoHsin Tung, Youzu Xu
    Cancer Medicine.2024;[Epub]     CrossRef
  • Survival of lung cancer patients according to screening eligibility using Korean Lung Cancer Registry 2014–2016
    Sangwon Lee, Eun Hye Park, Bo Yun Jang, Ye Ji Kang, Kyu-Won Jung, Hyo Soung Cha, Kui Son Choi
    Scientific Reports.2024;[Epub]     CrossRef
  • Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
    Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung
    Cancer Research and Treatment.2023; 55(1): 103.     CrossRef
  • Endobronchial ultrasound‐guided re‐biopsy of non–small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment
    Kyung Soo Hong, Jinmo Cho, Jong Geol Jang, Min Hye Jang, June Hong Ahn
    Thoracic Cancer.2023; 14(4): 363.     CrossRef
  • Stratifying non-small cell lung cancer patients using an inverse of the treatment decision rules: validation using electronic health records with application to an administrative database
    Min-Hyung Kim, Sojung Park, Yu Rang Park, Wonjun Ji, Seul-Gi Kim, Minji Choo, Seung-Sik Hwang, Jae Cheol Lee, Hyeong Ryul Kim, Chang-Min Choi
    BMC Medical Informatics and Decision Making.2023;[Epub]     CrossRef
  • Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer: Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09)
    Tae Hoon Lee, Hyunju Shin, Yong Chan Ahn, Min Kyu Kang, Changhoon Song, Woo Chul Kim, Sung Ho Moon, Jin Hee Kim, Jaeho Cho, Hae Jin Park, Heui Kwan Lee, Byoung Hyuck Kim, Hak Jae Kim
    Radiotherapy and Oncology.2023; 183: 109572.     CrossRef
  • A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
    Cheol-Kyu Park, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, In-Jae Oh
    Cancers.2023; 15(5): 1606.     CrossRef
  • All-round counterattack to conquer lung cancer
    Seung Hun Jang
    Journal of the Korean Medical Association.2023; 66(3): 154.     CrossRef
  • Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer
    Tae Hoon Lee, Joo-Hyun Chung, Hong-Gyun Wu, Suzy Kim, Joo Ho Lee, Bhumsuk Keam, Jin-Soo Kim, Ki Hwan Kim, Byoung Hyuck Kim, Hak Jae Kim
    Cancer Research and Treatment.2023; 55(3): 875.     CrossRef
  • Lung Cancer Screening in Asia: An Expert Consensus Report
    David Chi-Leung Lam, Chong-Kin Liam, Sita Andarini, Samina Park, Daniel S.W. Tan, Navneet Singh, Seung Hun Jang, Varut Vardhanabhuti, Antonio B. Ramos, Tomio Nakayama, Nguyen Viet Nhung, Kazuto Ashizawa, Yeun-Chung Chang, Jamsak Tscheikuna, Cong Cung Van,
    Journal of Thoracic Oncology.2023; 18(10): 1303.     CrossRef
  • New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment
    Peiyao Wang, Sophie Sun, Stephen Lam, William W. Lockwood
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • Sublobar Resection versus Stereotactic Body Radiation Therapy for Clinical Stage I Non–Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry
    Jeonghee Yun, Jong Ho Cho, Tae Hee Hong, Kyungmi Yang, Yong Chan Ahn, Hong Kwan Kim
    Cancer Research and Treatment.2023; 55(4): 1171.     CrossRef
  • Synthetic Tabular Data Based on Generative Adversarial Networks in Health Care: Generation and Validation Using the Divide-and-Conquer Strategy
    Ha Ye Jin Kang, Erdenebileg Batbaatar, Dong-Woo Choi, Kui Son Choi, Minsam Ko, Kwang Sun Ryu
    JMIR Medical Informatics.2023; 11: e47859.     CrossRef
  • Long-term Survival According to N Stage Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Non-small Cell Lung Cancer
    Bin Hwangbo, Eun Young Park, Bumhee Yang, Geon Kook Lee, Tae Sung Kim, Hyae Young Kim, Moon Soo Kim, Jong Mog Lee
    Chest.2022; 161(5): 1382.     CrossRef
  • Survival impact of prophylactic cranial irradiation in small-cell lung cancer in the modern era of magnetic resonance imaging staging
    Yu Jin Lim, Changhoon Song, Hak Jae Kim
    Radiation Oncology.2022;[Epub]     CrossRef
  • Lung Cancer Screening with Low-Dose Chest Computed Tomography
    Yeon Wook Kim
    The Korean Journal of Medicine.2022; 97(1): 42.     CrossRef
  • Association between clinical outcomes and local treatment in stage IV non‐small cell lung cancer patients with single extrathoracic metastasis
    Jeong Uk Lim, Hye Seon Kang, Ah Young Shin, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
    Thoracic Cancer.2022; 13(9): 1349.     CrossRef
  • Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
    Tae-Hwan Kim, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Heejun Son, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
    Scientific Reports.2022;[Epub]     CrossRef
  • Characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer in Korea
    Hye Seon Kang, Jung Uk Lim, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Ho Cheol Kim, Chang Min Choi, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Yeongdae Kim, Yoo-Duk Choi, Yang-Gun Suh, Jung-Eun Kim, Youn
    BMC Pulmonary Medicine.2022;[Epub]     CrossRef
  • Sex differences in the characteristics and survival of patients with non‐small‐cell lung cancer: A retrospective analytical study based on real‐world clinical data of the Korean population
    Da Som Jeon, Jin Woo Kim, Seul Gi Kim, Hyeong Ryul Kim, Si Yeol Song, Jae Cheol Lee, Wonjun Ji, Chang‐Min Choi, Ho Cheol Kim
    Thoracic Cancer.2022; 13(18): 2584.     CrossRef
  • Single-cell RNA sequencing analysis to explore immune cell heterogeneity and novel biomarkers for the prognosis of lung adenocarcinoma
    Yong Xu, Yao Wang, Leilei Liang, Nan Song
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
    Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim
    Thoracic Cancer.2021; 12(4): 444.     CrossRef
  • Active Treatment Improves Overall Survival in Extremely Older Non–Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
    Su Yeon Lee, Yoon-Ki Hong, Wonjun Ji, Jae Cheol Lee, Chang Min Choi
    Cancer Research and Treatment.2021; 53(1): 104.     CrossRef
  • A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
    Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
    Cancer Research and Treatment.2021; 53(1): 93.     CrossRef
  • Prognostic significance of genetic variants in GLUT1 in stage III non‐small cell lung cancer treated with radiotherapy
    Min Kyu Kang, Shin Yup Lee, Jin Eun Choi, Sun Ah Baek, Sook Kyung Do, Jeong Eun Lee, Jongmoo Park, Seung Soo Yoo, Sunha Choi, Kyung Min Shin, Ji Yun Jeong, Jae Yong Park
    Thoracic Cancer.2021; 12(6): 874.     CrossRef
  • Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer Patients
    Joon Young Choi, Wonjun Ji, Chang-Min Choi, Chaeuk Chung, Jae Myoung Noh, Cheol-Kyu Park, In-Jae Oh, Hong In Yoon, Hyeong Ryul Kim, Ho Young Kim, Chang Dong Yeo, Seung Hun Jang
    Tuberculosis and Respiratory Diseases.2021; 84(2): 105.     CrossRef
  • Recent Trends of Lung Cancer in Korea
    Jae Guk Lee, Ho Cheol Kim, Chang-Min Choi
    Tuberculosis and Respiratory Diseases.2021; 84(2): 89.     CrossRef
  • Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
    Hayoung Choi, Jae‐Kyeong Lee, Hyung‐Joo Oh, Min‐Seok Kim, Bo Gun Kho, Cheol Kyu Park, In‐Jae Oh, Young‐Chul Kim
    Thoracic Cancer.2021; 12(10): 1598.     CrossRef
  • Time‐varying effect of sex on prognosis of lung adenocarcinoma surgical patients in China
    Zezhou Wang, Miao Mo, Changming Zhou, Xiaoshuang Feng, Jie Shen, Ting Ye, Yang Zhang, Hong Hu, Haiquan Chen, Ying Zheng
    Thoracic Cancer.2021; 12(11): 1699.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
    Fernando Franco, Enric Carcereny, Maria Guirado, Ana L. Ortega, Rafael López-Castro, Delvys Rodríguez-Abreu, Rosario García-Campelo, Edel del Barco, Oscar Juan, Francisco Aparisi, Jose L. González-Larriba, Manuel Domine, Jose M. Trigo, Manuel Cobo, Sara C
    PLOS ONE.2021; 16(6): e0251761.     CrossRef
  • Survival Prediction of Lung Cancer Using Small-Size Clinical Data with a Multiple Task Variational Autoencoder
    Thanh-Hung Vo, Guee-Sang Lee, Hyung-Jeong Yang, In-Jae Oh, Soo-Hyung Kim, Sae-Ryung Kang
    Electronics.2021; 10(12): 1396.     CrossRef
  • Impact of coexistent preserved ratio impaired spirometry on the survival of patients with lung cancer: Analysis of data from the Korean Association for Lung Cancer Registry
    I. Re Heo, Ho Cheol Kim, Seung Jun Lee, Jung‐Wan Yoo, Sunmi Ju, Yi Yeong Jeong, Jong Deog Lee, Yu Ji Cho, Jong Hwan Jeong, Manbong Heo, Seung Woo Jung, Tae Hoon Kim
    Thoracic Cancer.2021; 12(18): 2478.     CrossRef
  • Lung Cancer in Korea
    Sehhoon Park, Chang-Min Choi, Seung-Sik Hwang, Yoon-La Choi, Hyae Young Kim, Young-Chul Kim, Young Tae Kim, Ho Yun Lee, Si Yeol Song, Myung-Ju Ahn
    Journal of Thoracic Oncology.2021; 16(12): 1988.     CrossRef
  • Multiple genome pattern analysis and signature gene identification for the Caucasian lung adenocarcinoma patients with different tobacco exposure patterns
    Yan-mei Dong, Li-da Qin, Yi-fan Tong, Qi-en He, Ling Wang, Kai Song
    PeerJ.2020; 8: e8349.     CrossRef
  • Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
    Seongho Park, Yoo‐Duk Choi, Jieun Kim, Bo‐Gun Kho, Cheol‐Kyu Park, In‐Jae Oh, Young‐Chul Kim
    Thoracic Cancer.2020; 11(2): 408.     CrossRef
  • Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
    Eunhyang Park, Hyo Sup Shim
    Cancer Research and Treatment.2020; 52(2): 543.     CrossRef
  • A New TTZ Feature Extracting Algorithm to Decipher Tobacco Related Mutation Signature Genes for the Personalized Lung Adenocarcinoma Treatment
    Qien He, Zhewei Qiu, Yifan Tong, Kai Song
    IEEE Access.2020; 8: 89031.     CrossRef
  • Épidémiologie des cancers du poumon en France : les tendances actuelles
    E. Giroux Leprieur, A. Vergnenègre, J. Trédaniel
    Revue des Maladies Respiratoires Actualités.2020; 12(2): 2S6.     CrossRef
  • Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers
    Yeon Wook Kim, Hye-Rin Kang, Byoung Soo Kwon, Sung Yoon Lim, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
    European Respiratory Journal.2020; 56(5): 2000177.     CrossRef
  • Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors
    Ji Soo Park, Beodeul Kang, Yehyun Park, Soo Jung Park, Jae Hee Cheon, Minkyu Jung, Seung Hoon Beom, Sang Joon Shin, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Kang Young Lee, Joong Bae Ahn, Nam Kyu Kim, Tae Il Kim
    Journal of Cancer Prevention.2019; 24(1): 48.     CrossRef
  • Épidémiologie des cancers du poumon en France: les tendances actuelles
    A. Vergnenègre, J. Trédaniel, L. Bigay-Gamé, O. Bylicki, J-C. Pairon, T. Urban, M. Colonna
    Revue des Maladies Respiratoires Actualités.2019; 11(3): 169.     CrossRef
  • 12,163 View
  • 541 Download
  • 52 Web of Science
  • 49 Crossref
Close layer
Case Report
Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease
Ho Cheol Kim, Jung Su Lee, Sang Hyung Kim, Hoon Sub So, Chang Yoon Woo, Jae Lyun Lee
Cancer Res Treat. 2013;45(4):349-353.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.349
AbstractAbstract PDFPubReaderePub
Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.

Citations

Citations to this article as recorded by  
  • The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
    Alessandra Cinque, Roberto Minnei, Matteo Floris, Francesco Trevisani
    Cancers.2022; 14(21): 5352.     CrossRef
  • Hereditary renal cell tumors: Clinicopathologic importance
    Harmanjot Singh, Mukul K. Divatia, Donghwa Baek, Jae Y. Ro
    annals of urologic oncology.2021;[Epub]     CrossRef
  • Von Hippel-Lindau Disease: Current Challenges and Future Prospects


    Sven Gläsker, Evelynn Vergauwen, Christian A Koch, Alexander Kutikov, Alexander O Vortmeyer
    OncoTargets and Therapy.2020; Volume 13: 5669.     CrossRef
  • The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
    Song Peng, Jun Zhang, Xintao Tan, Yiqiang Huang, Jing Xu, Natalie Silk, Dianzheng Zhang, Qiuli Liu, Jun Jiang
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights
    Maria I. Carlo, A. Ari Hakimi, Grant D. Stewart, Gennady Bratslavsky, James Brugarolas, Ying-Bei Chen, W. Marston Linehan, Eamonn R. Maher, Maria J. Merino, Kenneth Offit, Victor E. Reuter, Brian Shuch, Jonathan A. Coleman
    European Urology.2019; 76(6): 754.     CrossRef
  • The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel–Lindau Disease: A Retrospective Study of 32 Patients
    Kaifang Ma, Baoan Hong, Jingcheng Zhou, Yanqing Gong, Jiangyi Wang, Shengjie Liu, Xiang Peng, Bowen Zhou, Jiufeng Zhang, Haibiao Xie, Kenan Zhang, Lei Li, Desheng Cai, Zixin Wang, Lin Cai, Kan Gong
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease
    Gang Yuan, Qiuli Liu, Dali Tong, Gaolei Liu, Yuting Yi, Jun Zhang, Yao Zhang, Lin-ang Wang, Luofu Wang, Rongrong Chen, Yanfang Guan, Xin Yi, Weihua Lan, Jun Jiang
    Cancer Biology & Therapy.2018; 19(9): 766.     CrossRef
  • Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management
    Brian Shuch, Jin Zhang
    Journal of Clinical Oncology.2018; 36(36): 3560.     CrossRef
  • A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
    Su Jin Heo, Choong-kun Lee, Kyu Yeon Hahn, Gyuri Kim, Hyuk Hur, Sung Hoon Choi, Kyung Seok Han, Arthur Cho, Minkyu Jung
    Cancer Research and Treatment.2016; 48(1): 409.     CrossRef
  • Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease
    Akihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, Shoko Akiyama, Shunsuke Sugiyama, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Naomi Sato, Fumiyoshi Fujishima, Taro Shuin, Hideki Shimodaira, Chikashi Ishioka
    Internal Medicine.2016; 55(6): 629.     CrossRef
  • Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group
    Stéphane Oudard, Reza Elaidi, Mara Brizard, Céline Le Rest, Valérie Caillet, Sophie Deveaux, Gérard Benoit, Jean-Michel Corréas, Farida Benoudiba, Philippe David, Alain Gaudric, Pascal Hammel, Dominique Joly, Marc Olivier Timsit, Arnaud Méjean, Stéphane R
    Oncotarget.2016; 7(51): 85306.     CrossRef
  • Pharmacogenomic biomarkers for personalized cancer treatment
    C. Rodríguez‐Antona, M. Taron
    Journal of Internal Medicine.2015; 277(2): 201.     CrossRef
  • Pharmacological HIF2α inhibition improves VHL disease–associated phenotypes in zebrafish model
    Ana Martins Metelo, Haley R. Noonan, Xiang Li, Youngnam Jin, Rania Baker, Lee Kamentsky, Yiyun Zhang, Ellen van Rooijen, Jordan Shin, Anne E. Carpenter, Jing-Ruey Yeh, Randall T. Peterson, Othon Iliopoulos
    Journal of Clinical Investigation.2015; 125(5): 1987.     CrossRef
  • Molecular and immunologic markers of kidney cancer—potential applications in predictive, preventive and personalized medicine
    Amanda Mickley, Olga Kovaleva, Julia Kzhyshkowska, Alexei Gratchev
    EPMA Journal.2015;[Epub]     CrossRef
  • 11,959 View
  • 70 Download
  • 15 Web of Science
  • 14 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP